Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

LOS ANGELES--(BUSINESS WIRE)--AHF Hammers Gilead Over Continued Profiteering.

AHF Hammers Gilead Over Continued Profiteering

Chipotle

Ford Motor Company

Snap

V.F.

Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.

Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More

Gilead came up with a mixed fourth quarter late Tuesday as sales of its Covid treatment bolstered sales. GILD stock slipped in late trades.

Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short

Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% due to lower expenses.

Gilead quarterly revenue drops 4%, oral COVID drug fails trial

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About.

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead's base business, driven by both HIV and Oncology,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “The strength of the business provides a solid foundation as we enter a new catalyst-rich phase for the company. We are expecting several milestones in 2024, inclu.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Kyverna Therapeutics Inc

Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.

Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

Alkermes

Regeneron Pharmaceuticals

Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.

3 Top Pharma Stocks to Buy Now: February 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company's Board of Directors. Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics. Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup t.

Ted Love, MD, Joins Gilead Sciences' Board of Directors

Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Exploring Analyst Estimates for Gilead (GILD) Q4 Earnings, Beyond Revenue and EPS

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Shares in Arcus Biosciences Inc rose after Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) agreed to invest another $320 million as part of a tweaked collaboration agreement. Extending a multiple-drug partnership that began in 2020, Gilead will buy Arcus stock at $21 per share, compared to Monday's close price of $15.30.

Arcus rises, Gilead slips on expanded agreement

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite's median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient's T cells are collected, to product releas.

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Arcus Biosciences

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer drugs.

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies' joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

SPDR Dow Jones Industrial Average ETF

Entergy

iShares Bitcoin Trust

International Paper

JPMorgan Equity Premium Income ETF

Invesco QQQ

Schwab US Dividend Equity ETF

SPDR S&P 500 ETF Trust

SPDR Portfolio S&P 500 High Dividend ETF

Industrial Select Sector SPDR Fund

Consumer Staples Select Sector SPDR Fund

Rob Isbitts discusses the state of ETF business and the recent launch of spot Bitcoin ETFs.

Embracing The Mania And Yield At A Reasonable Price

Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors.

Biotech And Pharma Diversification Pays Off

Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilea.

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

Bristol-Myers

Johnson & Johnson

Legend Biotech

Novartis

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

Trodelvy did not perform well in an important clinical trial. Management is vowing to keep seeking other patient populations to treat with the drug.

Why Gilead Sciences Stock Got Mashed on Monday

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in the overall survival of patients with certain types of lung cancer. Shares of the biotech firm were down nearly 11% by midday Monday after the Phase 3 EVOKE-01 study did not meet the primary endpoint for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy or a checkpoint inhibitor.

News for Gilead Sciences Stock (GILD)